Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingre Moshen Granule (QMG) is a Traditional Chinese Medicine (TCM) herbal formulation used for the treatment of idiopathic membranous nephropathy (IMN), particularly in patients who are refractory to conventional Western therapies such as corticosteroids or immunosuppressive agents. It is typically administered orally as a granule and is often used in conjunction with other TCM recipes, such as the Shen No. 9 Recipe (SR). The therapeutic effect of QMG is thought to be mediated through the modulation of cellular immune responses, including the correction of abnormal interleukin-2 (IL-2) expression. Clinical studies have demonstrated that the combination of QMG and SR can achieve significant remission rates in patients with refractory IMN.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingre moshen.